Trade Vir Biotechnology VIR

VirBiotechnology live chart

instrument_fundamentals

Weekly Search
Weekly
Daily
date Close change Change (%) instr__open High Low

VirBiotechnology news

Latest news

Show more
Ava Grace 2025 Aug 04, 09:20

BOJ Rate Hike Expectations Surge After Trade Agreement Announcement

Noah Lee 2025 Aug 04, 02:20

Trump's Nuclear Rhetoric: Just a Diversion or Real Escalation?

Emma Rose 2025 Aug 04, 01:20

India Defies Trump's Threats, Continues Russian Oil Imports: Energy Security vs. Geopolitics

Sophia Claire 2025 Aug 04, 01:20

Trump's Tariffs on Switzerland: Recession Fears and Potential Deal Adjustments

Bank of England BoE
Tommy Yap 2025 Aug 02, 21:00

Week Ahead: Interest Rate Decisions from BoE in Focus

Forex Indices
Noah Lee 2025 Aug 02, 00:20

Market Review: Trump Tariffs, Fed Rate Hike Expectations, and Mixed Economic Data

Noah Lee 2025 Aug 01, 23:20

Market Review: Trump Tariffs, Fed Policy, Digital Assets, and Key Developments

Ava Grace 2025 Aug 01, 15:20

OPEC+ at a Crossroads: Production Hike and Future Market Challenges

Info

Spread

0.05

Spread (%)

0.9960 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

13:31 - 19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

instr__analysis_statistics

instr__open

---

instr__close

---

instr__52week_range

--- – ---

instr__market_cap

695337152

instr__shares_outstand

138238000

instr__earnings_date

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

instr__eps

-4.23

instrument_learn_more

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Markets.com Bonus Trading

related_instruments

view_all_instruments

latest_education_articles

Show more
Trustpilot